Eli Lilly
Portfolio in Switzerland · United States: 2 funded startups tracked by Uback, 2 of them in a ranking.
Portfolio on Uback2startups, 2 countries
In a ranking2ranked by AI-estimated valuation
On the Radar0eligible, not ranked
Latest deal trackedAug 2025Strand Therapeutics
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| HAYA Therapeutics | #32 Switzerland | Biotech › RNA medicines | Series A · USD 65M · May 2025 | Hundreds of M$ |
| Strand Therapeutics | #8 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series B · USD 153M · Aug 2025 | Hundreds of M$ |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
22025
Co-investors
Sofinnova Partners · Earlybird · ATHOS · +ND Capital · Alexandria · Amgen Ventures · Regeneron
Investors that joined the same rounds, as reported by public sources.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.